ERNA

+ Watchlist + Portfolio

Ernexa Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.62
52-Week Range: $3.18 – $71.50
Market Cap: $5.38M
P/E (TTM): —
EPS (TTM): -0.41
Dividend Yield: —

Advanced Metrics

Price/Book: 0.78
PEG Ratio: —
Return on Equity: -320.72%
Return on Assets: -105.56%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.01
Debt/Equity: 0.11
Total Debt: $349.00K
Free Cash Flow: $-5.93M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.70M

ERNA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$68.00K	$582.00K	$0.00
Cost of Revenue	$0.00	$236.00K	$96.00K	$0.00
Gross Profit	$0.00	-$168.00K	$486.00K	$0.00
Research & Development	$10.39M	$5.92M	$4.60M	$4.16M
Selling, General & Admin	$16.55M	$14.59M	$13.13M	$5.16M
Operating Expenses	$26.95M	$20.51M	$17.74M	$9.32M
Operating Income	-$26.95M	-$20.68M	-$17.25M	-$9.32M
EBITDA	-$24.01M	-$19.93M	-$36.12M	-$13.84M
Pretax Income	-$24.53M	-$21.67M	-$44.51M	-$14.13M
Income Tax	$45.00K	-$3.00K	$30.00K	-$45.00K
Net Income	-$24.58M	-$21.67M	-$44.54M	-$14.08M
Diluted EPS	-3022.50	-1530.00	-1224.00	-56.00
Diluted Shares	8136	14170	36400	252280

ERNA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.45M	$7.58M	$1.73M	$1.88M
Receivables	$951.00K	$425.00K	$437.00K	$845.00K
Current Assets	$13.68M	$9.60M	$2.35M	$3.13M
Total Assets	$22.28M	$49.13M	$5.27M	$5.83M
Current Liabilities	$7.65M	$6.57M	$2.94M	$3.11M
Long-Term Debt	$1.21M	$6.77M	—	—
Total Debt	$1.18M	$41.84M	$684.00K	$490.00K
Total Liabilities	$10.17M	$46.90M	$3.57M	$3.43M
Retained Earnings	-$165.30M	-$186.98M	-$231.54M	-$245.64M
Shareholders' Equity	$12.11M	$2.23M	$1.70M	$2.40M
Working Capital	$6.03M	$3.03M	-$586.00K	$20.00K

ERNA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$20.98M	-$20.41M	-$15.84M	-$7.02M
Capital Expenditure	-$297.00K	-$19.00K	-$369.00K	-$37.00K
Free Cash Flow	-$21.27M	-$20.43M	-$16.20M	-$7.05M
Depreciation & Amortisation	$497.00K	$1.12M	$1.64M	$263.00K
Stock-Based Compensation	$2.94M	$1.24M	$1.52M	$1.50M
Investing Cash Flow	-$47.00K	-$19.00K	-$365.00K	-$37.00K
Financing Cash Flow	$19.58M	$16.56M	$6.26M	$7.21M
Dividends Paid	-$16.00K	-$16.00K	$0.00	—
Net Change in Cash	-$1.44M	-$3.87M	-$9.94M	$155.00K

ERNA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.31M	$1.14M	$1.03M	$676.00K	$1.92M
Selling, General & Admin	$1.42M	$1.36M	$958.00K	$1.42M	$1.63M
Operating Expenses	$2.73M	$2.50M	$1.99M	$2.09M	$3.55M
Operating Income	-$2.73M	-$2.50M	-$1.99M	-$2.09M	-$3.55M
EBITDA	-$2.66M	-$2.45M	-$1.92M	-$6.81M	-$3.46M
Pretax Income	-$8.19M	-$3.14M	-$1.23M	-$1.56M	-$5.55M
Income Tax	$8.00K	$3.00K	$6.00K	-$62.00K	-$40.00K
Net Income	-$8.20M	-$3.14M	-$1.24M	-$1.50M	-$5.51M
Diluted EPS	-1444.00	-15.25	-3.75	—	-173.75
Diluted Shares	5680	207160	329040	—	31680

ERNA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.92M	$4.32M	$3.05M	$1.88M	$9.18M
Receivables	$156.00K	$154.00K	$153.00K	$845.00K	$95.00K
Current Assets	$2.21M	$4.79M	$3.38M	$3.13M	$10.00M
Total Assets	$5.06M	$7.58M	$6.17M	$5.83M	$10.54M
Current Liabilities	$10.44M	$2.65M	$2.14M	$3.11M	$3.46M
Total Debt	$2.88M	$593.00K	$552.00K	$490.00K	$389.00K
Total Liabilities	$11.01M	$3.14M	$2.60M	$3.43M	$3.68M
Retained Earnings	-$239.74M	-$242.88M	-$244.13M	-$245.64M	-$251.14M
Shareholders' Equity	-$5.95M	$4.44M	$3.57M	$2.40M	$6.86M
Working Capital	-$8.23M	$2.14M	$1.24M	$20.00K	$6.54M
Net Debt	$332.00K	—	—	—	—

ERNA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.06M	-$2.53M	-$1.27M	-$1.15M	-$2.26M
Capital Expenditure	—	—	—	-$15.00K	-$2.00K
Free Cash Flow	-$2.06M	-$2.53M	-$1.29M	-$1.16M	-$2.27M
Depreciation & Amortisation	$69.00K	$55.00K	$70.00K	$69.00K	$86.00K
Stock-Based Compensation	$502.00K	$368.00K	$293.00K	$333.00K	$309.00K
Investing Cash Flow	$0.00	$0.00	-$22.00K	-$15.00K	-$2.00K
Financing Cash Flow	$2.25M	$4.93M	$26.00K	$0.00	$9.56M
Dividends Paid	—	—	$0.00	—	—
Net Change in Cash	$189.00K	$2.40M	-$1.27M	-$1.16M	$7.29M

Market Snapshot

About

Ernexa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of metabolic diseases and other chronic conditions. The company focuses on discovering and developing small molecule drugs targeting metabolic pathways involved in conditions such as obesity, diabetes, and liver disease. Ernexa's pipeline includes multiple programs in preclinical and clinical development stages. The company employs a precision medicine approach to identify patient populations most likely to benefit from its therapeutic candidates. Further details about Ernexa's specific programs and development stage would require additional research as the company is relatively early in its public market lifecycle.